Efficacy of methotrexate in pediatric Crohnʼs disease: A French multicenter study

Abstract

MTX improved the clinical course in most pediatric CD patients who escaped or did not tolerate AZA. Short-time toxicity of MTX resulted in drug discontinuation in <10%. These data point to a beneficial and safe use of MTX in the treatment of pediatric CD.